Safety and efficacy of neoadjuvant chemoradiotherapy with moderately hypofractionated intensity-modulated radiotherapy for resectable pancreatic cancer: A prospective, open-label, phase II study.

Toshihiko MasuiKazuyuki NagaiTakayuki AnazawaYosuke KasaiAkitada YogoMichio YoshimuraTakashi MizowakiNorimitsu UzaAkihisa FukudaShigemi MatsumotoMasashi KanaiHiroyoshi IsodaYoshiya KawaguchiShinji UemotoEtsuro Hatano

Published in: Cancer medicine (2023)

This is the first prospective study of hypofractionated IMRT as neoadjuvant therapy for RPC. Hypofractionated NACIMRT for RPC could be safely introduced with a high induction rate of adjuvant chemotherapy, with an overall survival of 40.0 months.

Keyphrases

locally advanced
phase ii study
radiation therapy
rectal cancer
open label
radiation induced
squamous cell carcinoma
clinical trial
brain metastases
randomized controlled trial
early stage
small cell lung cancer
free survival
phase ii